329 related articles for article (PubMed ID: 25769621)
1. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.
Mancusi A; Ruggeri L; Urbani E; Pierini A; Massei MS; Carotti A; Terenzi A; Falzetti F; Tosti A; Topini F; Bozza S; Romani L; Tognellini R; Stern M; Aversa F; Martelli MF; Velardi A
Blood; 2015 May; 125(20):3173-82. PubMed ID: 25769621
[TBL] [Abstract][Full Text] [Related]
2. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
[TBL] [Abstract][Full Text] [Related]
3. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
[TBL] [Abstract][Full Text] [Related]
4. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
[TBL] [Abstract][Full Text] [Related]
5. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
Pende D; Marcenaro S; Falco M; Martini S; Bernardo ME; Montagna D; Romeo E; Cognet C; Martinetti M; Maccario R; Mingari MC; Vivier E; Moretta L; Locatelli F; Moretta A
Blood; 2009 Mar; 113(13):3119-29. PubMed ID: 18945967
[TBL] [Abstract][Full Text] [Related]
6. KIR gene mismatching and KIR/C ligands in liver transplantation: consequences for short-term liver allograft injury.
Legaz I; López-Álvarez MR; Campillo JA; Moya-Quiles MR; Bolarín JM; de la Peña J; Salgado G; Gimeno L; García-Alonso AM; Muro M; Miras M; Alonso C; Álvarez-López MR; Minguela A
Transplantation; 2013 Apr; 95(8):1037-44. PubMed ID: 23478359
[TBL] [Abstract][Full Text] [Related]
7. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
8. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
Hoseinian SA; Jafari D; Mahmoodi M; Alimoghaddam K; Ostadali M; Talebzadeh Bonakdar A; Foma AM; Yekaninejad MS; Amirzargar AA
Turk J Med Sci; 2018 Aug; 48(4):794-804. PubMed ID: 30119155
[TBL] [Abstract][Full Text] [Related]
9. HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.
Zhao XY; Chang YJ; Xu LP; Zhang XH; Liu KY; Li D; Huang XJ
Br J Cancer; 2014 Sep; 111(6):1080-8. PubMed ID: 25077441
[TBL] [Abstract][Full Text] [Related]
10. Donor KIR Genotype Impacts on Clinical Outcome after T Cell-Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients.
Escudero A; Martínez-Romera I; Fernández L; Valentín J; González-Vicent M; Vicario JL; Madero-Jarabo R; Diaz MÁ; Pérez-Martínez A
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2493-2500. PubMed ID: 30145228
[TBL] [Abstract][Full Text] [Related]
11. Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.
Marcenaro E; Carlomagno S; Pesce S; Della Chiesa M; Moretta A; Sivori S
J Leukoc Biol; 2011 Oct; 90(4):661-7. PubMed ID: 21791599
[TBL] [Abstract][Full Text] [Related]
12. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
[TBL] [Abstract][Full Text] [Related]
13. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
[TBL] [Abstract][Full Text] [Related]
14. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
[TBL] [Abstract][Full Text] [Related]
15. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
16. An overview of methods required to evaluate donor NK cell alloreactivity for haploidentical haemopoietic stem cell transplantation.
Velardi A
Methods Mol Biol; 2012; 882():469-76. PubMed ID: 22665250
[TBL] [Abstract][Full Text] [Related]
17. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
18. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT.
Sivori S; Carlomagno S; Falco M; Romeo E; Moretta L; Moretta A
Blood; 2011 Apr; 117(16):4284-92. PubMed ID: 21355085
[TBL] [Abstract][Full Text] [Related]
20. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
